Molecular pathogenesis of Parkinson's disease: Update

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 83, Issue 4, 2012, Pages 430-436

  Saiki, Shinji ^a   Sato, Shigeto ^a   Hattori, Nobutaka ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALPHA SYNUCLEIN; ATP13A2 PROTEIN; DJ 1 PROTEIN; F BOX PROTEIN; LEUCINE RICH REPEAT KINASE 2; PARKIN; PHOSPHOLIPASE A2 GROUP VI; PROTEIN FBX07; PROTEIN SERINE THREONINE KINASE; PTEN INDUCED KINASE 1; SERINE PROTEINASE OMI; UNCLASSIFIED DRUG;

ALPHA SYNUCLEIN GENE; ATP13A2 GENE; DJ 1 GENE; FBX07 GENE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GLUCOCEREBROSIDASE GENE; HUMAN; LEUCINE RICH REPEAT KINASE 2 GENE; MAPT GENE; MOLECULAR PATHOLOGY; MUTATOR GENE; NONHUMAN; OMI GENE; PARKIN GENE; PARKINSON DISEASE; PLA2G6 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTEN INDUCED KINASE 1 GENE; REVIEW;

ALPHA-SYNUCLEIN; ENDOPLASMIC RETICULUM-ASSOCIATED DEGRADATION; F-BOX PROTEINS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GROUP VI PHOSPHOLIPASES A2; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; ONCOGENE PROTEINS; PARKINSON DISEASE; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTON-TRANSLOCATING ATPASES; TAU PROTEINS; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 84858002150     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2011-301205     Document Type: Review

References (132)

1. Hatano T, Kubo S, Sato S, et al. Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease. J Neurochem 2009;111:1075-93.
2. Nuytemans K, Theuns J, Cruts M, et al. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 2010;31:763-80.
3. Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med 2009;11:e22.
4. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7. (Pubitemid 27443610)
5. Venda LL, Cragg SJ, Buchman VL, et al. a-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci 2010;33:559-68.
6. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009;41:1308-12.
7. Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009;41:1303-7.
8. Farrer M, Maraganore DM, Lockhart P, et al. a-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet 2001;10:1847-51. (Pubitemid 32899100)
9. Maraganore DM, de Andrade M, Elbaz A, et al. Collaborative analysis of alphasynuclein gene promoter variability and Parkinson disease. JAMA 2006;296:661-70. (Pubitemid 44200637)
10. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000;290:985-9.
11. Kruger R, Eberhardt O, Riess O, et al. Parkinson's disease: one biochemical pathway to fit all genes? Trends Mol Med 2002;8:236-40. (Pubitemid 34493642)
12. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000;287:1265-9. (Pubitemid 30112148)
13. Kahle PJ, Neumann M, Ozmen L, et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 2000;20:6365-73.
14. Giasson BI, Duda JE, Quinn SM, et al. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002;34:521-33. (Pubitemid 34628750)
15. Cookson MR, van der Brug M. Cell systems and the toxic mechanism(s) of alphasynuclein. Exp Neurol 2008;209:5-11.
16. Falsone SF, Kungl AJ, Rek A, et al. The molecular chaperone Hsp90 modulates intermediate steps of amyloid assembly of the Parkinson-related protein alphasynuclein. J Biol Chem 2009;284:31190-9.
17. Webb JL, Ravikumar B, Atkins J, et al. Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003;278:25009-13. (Pubitemid 37548663)
18. Cuervo AM, Stefanis L, Fredenburg R, et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004;305:1292-5. (Pubitemid 39129234)
19. Martinez-Vicente M, Talloczy Z, Kaushik S, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008;118:777-88.
20. Winslow AR, Chen CW, Corrochano S, et al. α-Synuclein impairs macroautophagy: implications for Parkinson's disease. J Cell Biol 2010;190:1023-37.
21. Brundin P, Li JY, Holton JL, et al. Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci 2008;9:741-5.
22. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-8. (Pubitemid 28207717)
23. Hattori N, Kitada T, Matsumine H, et al. Molecular genetic analysis of a novel parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the parkin gene in affected individuals. Ann Neurol 1998;44:935-41. (Pubitemid 28558255)
24. Matsumine H, Saito M, Shimoda-Matsubayashi S, et al. Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am J Hum Genet 1997;60:588-96. (Pubitemid 27097607)
25. Mori H, Kondo T, Yokochi M, et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998;51:890-2. (Pubitemid 28449284)
26. Takahashi H, Ohama E, Suzuki S, et al. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 1994;44:437-41. (Pubitemid 24098141)
27. Farrer M, Chan P, Chen R, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001;50:293-300. (Pubitemid 32848731)
28. Hilker R, Klein C, Ghaemi M, et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 2001;49:367-76. (Pubitemid 32202791)
29. Khan NL, Brooks DJ, Pavese N, et al. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 2002;125:2248-56.
30. Klein C, Pramstaller PP, Kis B, et al. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann Neurol 2000;48:65-71. (Pubitemid 30432432)
31. Pramstaller PP, Kis B, Eskelson C, et al. Phenotypic variability in a large kindred (Family LA) with deletions in the parkin gene. Mov Disord 2002;17:424-6. (Pubitemid 36041322)
32. Lincoln SJ, Maraganore DM, Lesnick TG, et al. Parkin variants in North American Parkinson's disease: cases and controls. Mov Disord 2003;18:1306-11. (Pubitemid 38263315)
33. Kay DM, Moran D, Moses L, et al. Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Ann Neurol 2007;61:47-54. (Pubitemid 46214243)
34. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000;25:302-5. (Pubitemid 30437317)
35. Matsuda N, Kitami T, Suzuki T, et al. Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro. J Biol Chem 2006;281:3204-9. (Pubitemid 43845931)
36. Shimura H, Schlossmacher MG, Hattori N, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001;293:263-9. (Pubitemid 32694735)
37. Chung KK, Zhang Y, Lim KL, et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 2001;7:1144-50. (Pubitemid 33010024)
38. Weihofen A, Thomas KJ, Ostaszewski BL, et al. Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking (dagger). Biochemistry 2009;48:2045-52.
39. Narendra D, Tanaka A, Suen DF, et al. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008;183:795-803.
40. Narendra D, Kane LA, Hauser DN, et al. p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. Autophagy 2010;6:1090-106.
41. Matsuda N, Sato S, Shiba K, et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol 2010;189:211-21.
42. Park J, Lee G, Chung J. The PINK1 - Parkin pathway is involved in the regulation of mitochondrial remodeling process. Biochem Biophys Res Commun 2009;378:518-23.
43. Valente EM, Bentivoglio AR, Dixon PH, et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 2001;68:895-900. (Pubitemid 32289735)
44. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004;304:1158-60. (Pubitemid 38661852)
45. Marongiu R, Brancati F, Antonini A, et al. Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. Hum Mutat 2007;28:98.
46. Hatano Y, Li Y, Sato K, et al. Novel PINK1 mutations in early-onset parkinsonism. Ann Neurol 2004;56:424-7. (Pubitemid 39166562)
47. Samaranch L, Lorenzo-Betancor O, Arbelo JM, et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 2010;133:1128-42.
48. Kawajiri S, Saiki S, Sato S, et al. Genetic mutations and functions of PINK1. Trends Pharmacol Sci 2011;32:573-80.
49. Beilina A, Van Der Brug M, Ahmad R, et al. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci U S A 2005;102:5703-8. (Pubitemid 40559623)
50. Pridgeon JW, Olzmann JA, Chin LS, et al. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 2007;5:e172.
51. Silvestri L, Caputo V, Bellacchio E, et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 2005;14:3477-92. (Pubitemid 41672130)
52. Sim CH, Lio DS, Mok SS, et al. C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum Mol Genet 2006;15:3251-62. (Pubitemid 44605504)
53. Murata H, Sakaguchi M, Jin Y, et al. A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1: activation of AKT via mTORC2. J Biol Chem 2011;286:7182-9.
54. Plun-Favreau H, Klupsch K, Moisoi N, et al. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol 2007;9:1243-52. (Pubitemid 350042356)
55. Strauss KM, Martins LM, Plun-Favreau H, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 2005;14:2099-111. (Pubitemid 41418010)
56. Wang X, Schwarz TL. The mechanism of Ca2+ -dependent regulation of kinesin-mediated mitochondrial motility. Cell 2009;136:163-74.
57. Liu W, Vives-Bauza C, Acin-Perez R, et al. PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease. PLoS One 2009;4:e4597.
58. Amo T, Sato S, Saiki S, et al. Mitochondrial membrane potential decrease caused by loss of PINK1 is not due to proton leak, but to respiratory chain defects. Neurobiol Dis 2011;41:111-8.
59. Deng H, Dodson MW, Huang H, et al. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci U S A 2008;105:14503-8.
60. Poole AC, Thomas RE, Andrews LA, et al. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci U S A 2008;105:1638-43. (Pubitemid 351346567)
61. Haque ME, Thomas KJ, D'Souza C, et al. Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc Natl Acad Sci U S A 2008;105:1716-21. (Pubitemid 351346580)
62. Clark IE, Dodson MW, Jiang C, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006;441:1162-6. (Pubitemid 43990738)
63. Park J, Lee SB, Lee S, et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006;441:1157-61. (Pubitemid 43990737)
64. Yang Y, Gehrke S, Imai Y, et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A 2006;103:10793-8. (Pubitemid 44078055)
65. Kawajiri S, Saiki S, Sato S, et al. PINK1 is recruited to mitochondria with parkin and associates with LC3 in mitophagy. FEBS Lett 2010;584:1073-9.
66. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011;12:9-14.
67. Abou-Sleiman PM, Healy DG, Quinn N, et al. The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol 2003;54:283-6. (Pubitemid 37072030)
68. Bandopadhyay R, Kingsbury AE, Cookson MR, et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 2004;127:420-30. (Pubitemid 38160326)
69. Neumann M, Muller V, Gorner K, et al. Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease. Acta Neuropathol 2004;107:489-96. (Pubitemid 38765389)
70. Olzmann JA, Bordelon JR, Muly EC, et al. Selective enrichment of DJ-1 protein in primate striatal neuronal processes: implications for Parkinson's disease. J Comp Neurol 2007;500:585-99.
71. Usami Y, Hatano T, Imai S, et al. DJ-1 associates with synaptic membranes. Neurobiol Dis 2011;43:651-62.
72. Miller DW, Ahmad R, Hague S, et al. L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J Biol Chem 2003;278:36588-95. (Pubitemid 37139990)
73. Goldberg MS, Pisani A, Haburcak M, et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial parkinsonism-linked gene DJ-1. Neuron 2005;45:489-96. (Pubitemid 40249861)
74. Wang Z, Liu J, Chen S, et al. DJ-1 modulates the expression of Cu/Zn-superoxide dismutase-1 through the Erk1/2-Elk1 pathway in neuroprotection. Ann Neurol 2011;70:591-9.
75. Lev N, Roncevic D, Ickowicz D, et al. Role of DJ-1 in Parkinson's disease. J Mol Neurosci 2006;29:215-25.
76. Fu K, Ren H, Wang Y, et al. DJ-1 inhibits TRAIL-induced apoptosis by blocking procaspase-8 recruitment to FADD. Oncogene. Published Online First: 25 July 2011. doi:10.1038/onc.2011.315.
77. Xiong H, Wang D, Chen L, et al. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 2009;119:650-60.
78. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600. (Pubitemid 39531224)
79. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-7. (Pubitemid 39531225)
80. Berwick DC, Harvey K. LRRK2 signaling pathways: the key to unlocking neurodegeneration? Trends Cell Biol 2011;21:257-65.
81. Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 2010;11:791-7.
82. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005;365:415-16. (Pubitemid 40179229)
83. Wszolek ZK, Pfeiffer RF, Tsuboi Y, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004;62:1619-22. (Pubitemid 38608210)
84. Ross OA, Toft M, Whittle AJ, et al. Lrrk2 and Lewy body disease. Ann Neurol 2006;59:388-93. (Pubitemid 43202496)
85. Dachsel JC, Ross OA, Mata IF, et al. Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. Acta Neuropathol 2007;113:601-6. (Pubitemid 46672607)
86. Galter D, Westerlund M, Carmine A, et al. LRRK2 expression linked to dopamine-innervated areas. Ann Neurol 2006;59:714-19.
87. Hatano T, Kubo S, Imai S, et al. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 2007;16:678-90. (Pubitemid 46585667)
88. Biskup S, Moore DJ, Celsi F, et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 2006;60:557-69. (Pubitemid 44871798)
89. Smith WW, Pei Z, Jiang H, et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A 2005;102:18676-81. (Pubitemid 43011285)
90. Ng CH, Mok SZ, Koh C, et al. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci 2009;29:11257-62.
91. Venderova K, Kabbach G, Abdel-Messih E, et al. Leucine-rich repeat kinase 2 interacts with parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Hum Mol Genet 2009;18:4390-404.
92. Chan D, Citro A, Cordy JM, et al. Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). J Biol Chem 2011;286:16140-9.
93. Angeles DC, Gan BH, Onstead L, et al. Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum Mutat 2011;32:1390-7.
94. Dusonchet J, Kochubey O, Stafa K, et al. A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J Neurosci 2011;31:907-12.
95. Li X, Wang QJ, Pan N, et al. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One 2011;6:e17153.
96. Najim al-Din AS, Wriekat A, Mubaidin A, et al. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand 1994;89:347-52. (Pubitemid 24163649)
97. Ramirez A, Heimbach A, Grundemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006;38:1184-91. (Pubitemid 44470365)
98. Gitler AD, Chesi A, Geddie ML, et al. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 2009;41:308-15.
99. Ugolino J, Fang S, Kubisch C, et al. Mutant Atp13a2 proteins involved in parkinsonism are degraded by ER-associated degradation and sensitize cells to ERstress induced cell death. Hum Mol Genet 2011;20:3565-77.
100. Tan J, Zhang T, Jiang L, et al. Regulation of intracellular manganese hemeostasis by kufor-rakeb syndrome associated ATP13A2. J Biol Chem 2011;286:29654-62.
101. Kawamoto Y, Kobayashi Y, Suzuki Y, et al. Accumulation of HtrA2/Omi in neuronal and glial inclusions in brains with alpha-synucleinopathies. J Neuropathol Exp Neurol 2008;67:984-93.
102. Kruger R, Sharma M, Riess O, et al. A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Neurobiol Aging 2011;32:548 e9-18.
103. Suzuki Y, Takahashi-Niki K, Akagi T, et al. Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways. Cell Death Differ 2004;11:208-16. (Pubitemid 38159645)
104. Martins LM. The serine protease Omi/HtrA2: a second mammalian protein with a reaper-like function. Cell Death Differ 2002;9:699-701. (Pubitemid 34778035)
105. Martins LM, Morrison A, Klupsch K, et al. Neuroprotective role of the reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol 2004;24:9848-62. (Pubitemid 39458812)
106. Li B, Hu Q, Wang H, et al. Omi/HtrA2 is a positive regulator of autophagy that facilitates the degradation of mutant proteins involved in neurodegenerative diseases. Cell Death Differ 2010;17:1773-84.
107. Morgan NV, Westaway SK, Morton JE, et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006;38:752-4. (Pubitemid 43980594)
108. Paisan-Ruiz C, Bhatia KP, Li A, et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 2009;65:19-23.
109. Yoshino H, Tomiyama H, Tachibana N, et al. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology 2010;75:1356-61.
110. Jenkins CM, Wolf MJ, Mancuso DJ, et al. Identification of the calmodulin-binding domain of recombinant calcium-independent phospholipase A2beta. Implications for structure and function. J Biol Chem 2001;276:7129-35.
111. Wang Z, Ramanadham S, Ma ZA, et al. Group VIA phospholipase A2 forms a signaling complex with the calcium/calmodulin-dependent protein kinase IIbeta expressed in pancreatic islet beta-cells. J Biol Chem 2005;280:6840-9. (Pubitemid 40341239)
112. Shojaee S, Sina F, Banihosseini SS, et al. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. Am J Hum Genet 2008;82:1375-84.
113. Di Fonzo A, Dekker MC, Montagna P, et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 2009;72:240-5.
114. Pankratz N, Wilk JB, Latourelle JC, et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 2009;124:593-605.
115. Edwards TL, Scott WK, Almonte C, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 2010;74:97-109.
116. Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 2010;42:781-5.
117. Spencer CC, Plagnol V, Strange A, et al. Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet 2010;20:345-53.
118. Liu X, Cheng R, Verbitsky M, et al. Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population. BMC Med Genet 2011;12:104.
119. Do CB, Tung JY, Dorfman E, et al. Web-based genome-wide association study identifies two novel Loci and a substantial genetic component for Parkinson's disease. PLoS Genet 2011;7:e1002141.
120. Hruska KS, Goker-Alpan O, Sidransky E. Gaucher disease and the synucleinopathies. J Biomed Biotechnol 2006;2006:78549.
121. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651-61.
122. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004;351:1972-7. (Pubitemid 39447138)
123. Mata IF, Samii A, Schneer SH, et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol 2008;65:379-82. (Pubitemid 351398524)
124. De Marco EV, Annesi G, Tarantino P, et al. Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. Mov Disord 2008;23:460-3.
125. Morris HR, Lees AJ, Wood NW. Neurofibrillary tangle parkinsonian disorders - tau pathology and tau genetics. Mov Disord 1999;14:731-6. (Pubitemid 29509614)
126. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 2006;59:449-58. (Pubitemid 43358065)
127. Tayebi N, Walker J, Stubblefield B, et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 2003;79:104-9. (Pubitemid 36693928)
128. Goker-Alpan O, Stubblefield BK, Giasson BI, et al. Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol 2010;120:641-9.
129. Cullen V, Sardi SP, Ng J, et al. Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing. Ann Neurol 2011;69:940-53.
130. Yap TL, Gruschus JM, Velayati A, et al. Alpha-synuclein interacts with glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem 2011;286:28080-8.
131. Hardy J. No definitive evidence for a role for the environment in the etiology of Parkinson's disease. Mov Disord 2006;21:1790-1. (Pubitemid 44742228)
132. Deng X, Dzamko N, Prescott A, et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol 2011;7:203-5.